Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
Antiinflammatory therapy with canakinumab for atherosclerotic disease
CANTOS Trial Group
Department of Medicine
Division of Cardiology
Penn State Heart and Vascular Institute
Research output
:
Contribution to journal
›
Article
›
peer-review
6822
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Antiinflammatory therapy with canakinumab for atherosclerotic disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Atherosclerotic Disease
100%
Anti-inflammatory Therapy
100%
Placebo
75%
Confidence Interval
62%
Hazard Ratio
37%
Lipid Levels
37%
Interleukin-1β
25%
Placebo Groups
25%
High-sensitivity C-reactive Protein (hs-CRP)
25%
C-reactive Protein Level
25%
Inflammation
12%
Clinical Data
12%
Hospitalization
12%
Cardiovascular Risk
12%
Low Dose Rate
12%
No Significant Difference
12%
High Incidence
12%
Fatal Infection
12%
Statistical Significance
12%
Cardiovascular Mortality
12%
Incidence Rate
12%
All-cause Mortality
12%
Innate Immunity
12%
Mortality Hazard
12%
Antibody Targeting
12%
Recurrent Cardiovascular Events
12%
Revascularization
12%
Nonfatal Myocardial Infarction
12%
Therapeutic Monoclonal Antibody
12%
Previous Myocardial Infarction
12%
Randomized Double-blind Trial
12%
Stable Angina
12%
Nonfatal Stroke
12%
Atherothrombosis
12%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Diseases
100%
Interleukin 1
25%
C Reactive Protein
25%
Heart Infarction
25%
Inflammation
12%
Infection
12%
All Cause Mortality
12%
Monoclonal Antibody
12%
Thrombosis
12%
Cerebrovascular Accident
12%
Unstable Angina Pectoris
12%